Woburn, MA (May 10, 2004) – U.S. Genomics has been awarded a $7.5 million phase I contract by the U.S. Department of Homeland Security Advanced Research Project Agency (HSARPA) to develop a sophisticated biological sensor for bio-defense applications. Under the 18-month contract, the Company will tailor its DNA mapping technology to detect and identify any airborne pathogen, including anthrax and smallpox.

U.S. Genomics’ DNA mapping technology combines simplicity of use with a uniquely broad spectrum of effectiveness. Using a universal reagent that can detect and identify any pathogen, the technology produces a genetic signature unique to each organism. Additionally, U.S. Genomics’ approach has the potential to identify genetically modified species, such as those that may have been deliberately engineered to deceive traditional detection techniques. Unlike other detection technologies, U.S. Genomics’ detection technology does not require amplification or the use of pathogen-specific reagents for detection of each threat organism.

“It is a privilege to work with the U.S. Department of Homeland Security on such a crucial project. We believe the unique pathogenic detection capabilities of our technology can substantially improve the security and safety of our citizens,” said Stephen P. DeFalco, Chairman and CEO of U.S. Genomics. “Our DNA mapping platform is being developed as a powerful tool for genetic analysis and infectious disease diagnostics. This new contract enables us to extend the platform for bio-defense applications.”

HSARPA's grant to U.S. Genomics is one of 14 awarded to private sector companies to conduct research and development leading to next-generation biological detection sensors and systems. The Agency's vision is to develop a platform to monitor for bacteria, viruses, and other toxins that could be deployed in airports, government buildings, and larger commercial complexes. Implementation of such a system would result in the protection of thousands of public areas.

"The ability to monitor public spaces for potential threats is a key element of our efforts to ensure the safety of our citizens," said Dr. David Bolka, Director of HSARPA. "We are pleased to be working with U.S. Genomics to further development of their technology for pathogen identification."



The Department of Homeland Security was created after the events of September 11th, 2001 to provide a unifying core for the vast national network of organizations and institutions involved in efforts to secure the nation and improve the security and safety of U.S. citizens. Detection and identification of dangerous biological agents is core to the Department’s mission, and rapid identification of such agents represents a critical first step in facilitating appropriate countermeasures.

About U.S. Genomics, Inc.
U.S. Genomics is a leading marketer and developer of technologies that allow genetics, functional genomics, and diagnostics to be performed at the single molecule level. The company’s technology platform can directly analyze individual molecules of DNA, RNA, and proteins without the need for amplification and combines advances in nanofluidics, optical engineering, and novel labeling strategies. The technology has life sciences applications in the areas of research, drug discovery and development, and diagnostics, and longer-term it will provide a platform to advance our understanding of diseases for individualized drug development. Founded in 1997, U.S. Genomics is located in Woburn, Massachusetts. For more information, please visit www.usgenomics.com.